These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27576135)

  • 41. ADAM17 as a therapeutic target in multiple diseases.
    Arribas J; Esselens C
    Curr Pharm Des; 2009; 15(20):2319-35. PubMed ID: 19601834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.
    Hara H; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Nakatsuka R; Harada E; Nishigaki T; Takahashi Y; Nojima S; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Morii E; Mori M; Doki Y; Naka T
    Br J Cancer; 2016 Jun; 115(1):66-75. PubMed ID: 27310703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional Characterization of Colon Cancer-Associated Mutations in
    Pavlenko E; Cabron AS; Arnold P; Dobert JP; Rose-John S; Zunke F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control of ADAM17 activity by regulation of its cellular localisation.
    Lorenzen I; Lokau J; Korpys Y; Oldefest M; Flynn CM; Künzel U; Garbers C; Freeman M; Grötzinger J; Düsterhöft S
    Sci Rep; 2016 Oct; 6():35067. PubMed ID: 27731361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations.
    Tholen S; Wolf C; Mayer B; Knopf JD; Löffek S; Qian Y; Kizhakkedathu JN; Biniossek ML; Franzke CW; Schilling O
    J Proteome Res; 2016 May; 15(5):1402-17. PubMed ID: 27089454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The shedding protease ADAM17: Physiology and pathophysiology.
    Zunke F; Rose-John S
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2059-2070. PubMed ID: 28705384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways.
    Rubina A; Patel M; Nightingale K; Potts M; Fielding CA; Kollnberger S; Lau B; Ladell K; Miners KL; Nichols J; Nobre L; Roberts D; Trinca TM; Twohig JP; Vlahava VM; Davison AJ; Price DA; Tomasec P; Wilkinson GWG; Weekes MP; Stanton RJ; Wang ECY
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303155120. PubMed ID: 37561786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.
    Tang B; Li X; Maretzky T; Perez-Aguilar JM; McIlwain D; Xie Y; Zheng Y; Mak TW; Weinstein H; Blobel CP
    FASEB J; 2020 Apr; 34(4):4956-4969. PubMed ID: 32103528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunomodulatory role of metalloproteinase ADAM17 in tumor development.
    Wang K; Xuan Z; Liu X; Zheng M; Yang C; Wang H
    Front Immunol; 2022; 13():1059376. PubMed ID: 36466812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
    Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
    Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium.
    Ma X; Takahashi Y; Wu W; Liang W; Chen J; Chakraborty D; Li Y; Du Y; Benyajati S; Ma JX
    J Biol Chem; 2021 Oct; 297(4):101185. PubMed ID: 34509473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interplay between APP and glypican-1 processing and α-synuclein aggregation in undifferentiated and differentiated human neural progenitor cells.
    Cheng F; Fransson LÅ; Mani K
    Glycobiology; 2023 May; 33(4):325-341. PubMed ID: 36790131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
    Sharma A; Bender S; Zimmermann M; Riesterer O; Broggini-Tenzer A; Pruschy MN
    Clin Cancer Res; 2016 Sep; 22(17):4428-39. PubMed ID: 27076628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. To cut or not to cut: New rules for proteolytic shedding of membrane proteins.
    Lichtenthaler SF; Meinl E
    J Biol Chem; 2020 Aug; 295(35):12353-12354. PubMed ID: 32859721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Arai J; Goto K; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Kaise Y; Lim LA; Yoshida H; Kato N
    Int J Cancer; 2018 Nov; 143(10):2575-2583. PubMed ID: 29873070
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.
    Kanzaki H; Shinohara F; Suzuki M; Wada S; Miyamoto Y; Yamaguchi Y; Katsumata Y; Makihira S; Kawai T; Taubman MA; Nakamura Y
    Sci Rep; 2016 Aug; 6():32259. PubMed ID: 27573075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44.
    Stoeck A; Keller S; Riedle S; Sanderson MP; Runz S; Le Naour F; Gutwein P; Ludwig A; Rubinstein E; Altevogt P
    Biochem J; 2006 Feb; 393(Pt 3):609-18. PubMed ID: 16229685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of glypican-1 in regulating multiple cellular signaling pathways.
    Pan J; Ho M
    Am J Physiol Cell Physiol; 2021 Nov; 321(5):C846-C858. PubMed ID: 34550795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma.
    Uchida S; Serada S; Suzuki Y; Funajima E; Kitakami K; Dobashi K; Tamatani S; Sato Y; Beppu T; Ogasawara K; Naka T
    Neoplasia; 2024 Apr; 50():100982. PubMed ID: 38417223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADAM17 cleaves the insulin receptor ectodomain on endothelial cells and causes vascular insulin resistance.
    Ghiarone T; Castorena-Gonzalez JA; Foote CA; Ramirez-Perez FI; Ferreira-Santos L; Cabral-Amador FJ; de la Torre R; Ganga RR; Wheeler AA; Manrique-Acevedo C; Padilla J; Martinez-Lemus LA
    Am J Physiol Heart Circ Physiol; 2022 Oct; 323(4):H688-H701. PubMed ID: 36018759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.